Published in Mediators Inflamm on January 28, 2016
miR-940 Suppresses Tumor Cell Invasion and Migration via Regulation of CXCR2 in Hepatocellular Carcinoma. Biomed Res Int (2016) 0.77
Mast cell phenotype, TNFα expression and degranulation status in non-small cell lung cancer. Sci Rep (2016) 0.75
Neutrophil count and percentage: potential independent prognostic indicators for advanced cancer patients in a palliative care setting. Oncotarget (2017) 0.75
Whole genome gene expression changes and hematological effects of rikkunshito in patients with advanced non-small cell lung cancer receiving first line chemotherapy. Exp Ther Med (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Alternative activation of macrophages. Nat Rev Immunol (2003) 27.53
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A (2013) 16.74
Lung cancer. N Engl J Med (2008) 13.49
Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 13.47
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Resolution of inflammation: the beginning programs the end. Nat Immunol (2005) 9.81
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol (2002) 8.27
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21
Role of CD47 as a marker of self on red blood cells. Science (2000) 7.00
Lung cancer in never smokers--a different disease. Nat Rev Cancer (2007) 6.41
Corpse clearance defines the meaning of cell death. Nature (2000) 6.01
Macrophage polarization comes of age. Immunity (2005) 5.67
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell (2009) 5.30
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell (2009) 5.22
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A (2012) 4.20
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A (2009) 3.87
International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer (2005) 3.81
Integrin-associated protein (CD47) and its ligands. Trends Cell Biol (2001) 3.79
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37
New vistas on macrophage differentiation and activation. Eur J Immunol (2007) 2.99
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res (2015) 2.97
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol (2015) 2.92
CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med (2001) 2.75
Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. Science (1996) 2.55
Phagocytosis and innate immunity. Curr Opin Immunol (2002) 2.47
Pathology of lung cancer. Clin Chest Med (2011) 2.40
Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol (2008) 2.39
Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol (2008) 2.26
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med (1991) 2.11
Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding. J Cell Biol (1993) 2.10
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer (2014) 2.08
[National consensus of diagnosis and treatment of non-small cell lung cancer]. Rev Invest Clin (2013) 2.04
The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer (2010) 2.03
Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol (2005) 1.98
CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A (2011) 1.91
Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol (2007) 1.86
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol (2012) 1.84
Macrophages as mediators of tumor immunosurveillance. Trends Immunol (2010) 1.80
Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J (2009) 1.80
The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu Rev Immunol (2013) 1.78
Inflammation: a driving force speeds cancer metastasis. Cell Cycle (2009) 1.78
Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol (1995) 1.74
Signal regulatory protein (SIRPalpha), a cellular ligand for CD47, regulates neutrophil transmigration. J Biol Chem (2002) 1.63
Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res (2001) 1.62
The role of CD47 in neutrophil transmigration. Increased rate of migration correlates with increased cell surface expression of CD47. J Biol Chem (2001) 1.55
Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med (2009) 1.47
Multifaceted link between cancer and inflammation. Biosci Rep (2012) 1.39
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol (2016) 1.39
Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res (2012) 1.37
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest (2014) 1.33
The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer (2014) 1.33
Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA. Am J Respir Crit Care Med (2009) 1.31
Cancer stem cells in bladder cancer: a revisited and evolving concept. Curr Opin Urol (2010) 1.23
Neutrophils in innate and adaptive immunity. Semin Immunopathol (2013) 1.23
The effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation. Biomaterials (2011) 1.17
Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc Natl Acad Sci U S A (2013) 1.16
Involvement of inflammatory mediators in macrophage antitumor activity. J Leukoc Biol (1993) 1.15
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract (2014) 1.13
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion (2007) 1.11
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res (2015) 1.09
Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. J R Coll Surg Edinb (2000) 1.09
Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. Oncologist (2015) 1.08
T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma (2009) 1.05
Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces. Biomaterials (2012) 1.04
Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer (2012) 1.02
Macrophage damage in relation to the pathogenesis of lung diseases. Environ Health Perspect (1980) 1.01
Lessons from common markers of tumor-initiating cells in solid cancers. Cell Mol Life Sci (2011) 0.99
Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res (2015) 0.97
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. Pharmacotherapy (2015) 0.97
Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression. Sci Rep (2015) 0.94
CD47 knockout mice exhibit improved recovery from spinal cord injury. Neurobiol Dis (2010) 0.93
CD47 signaling pathways controlling cellular differentiation and responses to stress. Crit Rev Biochem Mol Biol (2015) 0.90
Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations. Cancer Sci (2015) 0.90
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology (2016) 0.89
IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma. Int J Cancer (1989) 0.89
Activation of CD47 receptors causes proliferation of human astrocytoma but not normal astrocytes via an Akt-dependent pathway. Glia (2011) 0.88
Peptide-mediated inhibition of neutrophil transmigration by blocking CD47 interactions with signal regulatory protein alpha. J Immunol (2004) 0.88
SIRPbeta1 is expressed as a disulfide-linked homodimer in leukocytes and positively regulates neutrophil transepithelial migration. J Biol Chem (2005) 0.87
The CD47-SIRPα signalling system: its physiological roles and therapeutic application. J Biochem (2014) 0.87
Aggressive treatment of primary tumor in patients with non-small-cell lung cancer and exclusively brain metastases. Clin Lung Cancer (2012) 0.87
Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox". Lung Cancer (2015) 0.86
Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget (2015) 0.86
Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med (2013) 0.85
Technical advance: immunophenotypical characterization of human neutrophil differentiation. J Leukoc Biol (2011) 0.85
Inflammation-induced proteolytic processing of the SIRPα cytoplasmic ITIM in neutrophils propagates a proinflammatory state. Nat Commun (2013) 0.85
Decreased CD47 expression during spontaneous apoptosis targets neutrophils for phagocytosis by monocyte-derived macrophages. Early Hum Dev (2009) 0.84
Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. Drugs Context (2015) 0.84
Macrophage engulfment of a cell or nanoparticle is regulated by unavoidable opsonization, a species-specific 'Marker of Self' CD47, and target physical properties. Curr Opin Immunol (2015) 0.83
Lung carcinomas decrease the number of monocytes/macrophages (CD14+ cells) that produce TNF-alpha. Clin Immunol (2006) 0.83
Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. Ann Oncol (2014) 0.83